Updated:
Revelation Pharma Corporation
George Bickerstaff's Revelation Pharma consolidates specialty compounding pharmacies across the U.S. through a buy-and-build strategy.
Revelation Pharma Corporation
Revelation Pharma Corporation operates as a strategic consolidator in the specialty pharmacy compounding sector, led by Chairman and CEO George W. Bickerstaff, III. Bickerstaff's prior roles include Managing Director of MMC Group, a healthcare turnaround and restructuring firm, and CFO of Novartis Pharma AG. The firm targets acquisitions of independent 503A and 503B compounding pharmacies, driven by increasing provider demand for customized medications, sterile preparations, and hospital outsourcing. The firm's strategy centers on a buy-and-build model within pharmaceutical compounding, covering sterile preparations, non-sterile compounds, and clinical nutrition. Revelation provides centralized operational support—quality systems, regulatory compliance, and marketing—to its network of acquired pharmacies. Its footprint spans multiple states through wholly-owned subsidiaries, including locations confirmed in Tennessee, Georgia, Michigan, and Colorado. Confirmed acquisitions under the Revelation platform include University Compounding Pharmacy, a San Diego-based 503A and 503B facility, and Town & Country Compounding, a provider of complex sterile injectables. The firm has executed multiple acquisitions since 2019, expanding its national network of compounding pharmacies under a unified holding structure. While total AUM and team headcount remain undisclosed, the firm operates through a decentralized model where pharmacy founders often retain clinical roles post-acquisition. May 2023 saw an undisclosed capital raise to support its ongoing acquisition pipeline, extending a period of active dealmaking across the specialty pharmacy space. Revelation's structural differentiator lies in its application of a traditional private-equity roll-up playbook to a heavily regulated clinical environment. Rather than launching a single operating company, the firm acquires existing pharmacies with established licenses, payer contracts, and referring-provider relationships, then layers on centralized compliance and financial rigor. This model allows it to enter new markets efficiently while navigating the state-level patchwork of compounding regulation.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Denver
Corporate office
Denver, CO, United States
Principals
George W. Bickerstaff, III
Chairman and Chief Executive Officer
Sector focus
Frequently asked questions
What is Revelation Pharma's core business model?
Revelation Pharma acquires existing specialty compounding pharmacies, typically those with 503A and 503B designations, and integrates them into a centralized corporate structure. The firm provides operational and regulatory support while the acquired pharmacies continue to serve their local markets. This buy-and-build strategy is designed to capture market share in a highly fragmented and regulated sector.
Who runs investment decisions at Revelation Pharma?
George W. Bickerstaff, III, serves as Chairman and CEO, leading the firm's acquisition strategy and capital allocation. His background includes healthcare private equity, operational restructuring, and senior pharmaceutical finance roles. Acquisition decisions are driven from the executive level, targeting pharmacies with strong local relationships and regulatory compliance histories.
What types of pharmacies does Revelation Pharma acquire?
The firm acquires 503A compounding pharmacies, which fill patient-specific prescriptions, and 503B outsourcing facilities, which produce larger batches of sterile preparations for hospitals and clinics. The target profile typically includes established, independent pharmacies with existing provider networks. They focus on both sterile preparations, like injectables for hospital systems, and non-sterile customized medications.
How does Revelation Pharma create value after an acquisition?
Revelation adds centralized functions—including group purchasing, quality assurance systems, regulatory compliance, and professional marketing—to reduce overhead and improve margins at the pharmacy level. The holding company structure allows it to standardize processes while allowing local pharmacists to maintain clinical autonomy. This is intended to improve growth rates compared to independent pharmacies operating alone.
Is Revelation Pharma a private equity firm or a family office?
Revelation Pharma operates as a holding company and asset manager, deploying a consolidation strategy common in private equity. It is not structured as a single-family office. The firm raises and deploys capital specifically to acquire and operate compounding pharmacies rather than managing the wealth of a single family.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: